Table 3 Characteristics of 320 patients who received first-line platinum-based or platinum-free chemotherapies with different HR gene alteration statuses
|  | gHRmut (N = 32) | gHRwt (N = 288) | Overall (N = 320) |
|---|---|---|---|
Gender | |||
 Female | 16 (50.0%) | 125 (43.4%) | 141 (44.1%) |
 Male | 16 (50.0%) | 163 (56.6%) | 179 (55.9%) |
Age, median (IQR) | 61.7 (52.5, 68.9) | 62.8 (55.3, 68.6) | 62.8 (55.2, 68.8) |
Location | |||
 Head | 10 (31.3%) | 74 (25.7%) | 84 (26.3%) |
 Uncinate process | 0 (0%) | 12 (4.2%) | 12 (3.8%) |
 Body | 6 (18.8%) | 74 (25.7%) | 80 (25.0%) |
 Tail | 6 (18.8%) | 59 (20.5%) | 65 (20.3%) |
 Overlapping area | 10 (31.3%) | 69 (24.0%) | 79 (24.7%) |
Stage | |||
 III | 13 (40.6%) | 94 (32.6%) | 107 (33.4%) |
 IV | 19 (59.4%) | 194 (67.4%) | 213 (66.6%) |
Family history | |||
 Yes | 19 (59.4%) | 160 (55.6%) | 179 (55.9%) |
 No | 12 (37.5%) | 125 (43.4%) | 137 (42.8%) |
 Unknown | 1 (3.1%) | 3 (1.0%) | 4 (1.3%) |
ECOG PS | |||
 0–1 | 28 (87.5%) | 260 (90.3%) | 288 (90.0%) |
 ≥ 2 | 4 (12.5%) | 28 (9.7%) | 32 (10.0%) |
Baseline albumin, g/dL | |||
 Median (IQR) | 4.200 (3.700, 4.500) | 4.100 (3.800, 4.400) | 4.100 (3.800, 4.400) |
 Not recorded | 7 (21.9%) | 85 (29.5%) | 92 (28.8%) |
Baseline CA-19.9, U/mL | |||
 Median (IQR) | 2244 (255.1, 5772) | 444.5 (64.6, 3030) | 471.0 (76.0, 3561) |
 Not recorded | 5 (15.6%) | 50 (17.4%) | 55 (17.2%) |
Enrollment in clinical trial | |||
 Yes | 27 (84.4%) | 220 (76.4%) | 247 (77.2%) |
 No | 5 (15.6%) | 68 (23.6%) | 73 (22.8%) |
1L platinum-based | |||
 SLOG | 12 (37.5%) | 141 (49.0%) | 153 (47.8%) |
 mFOLFIRINOX | 1 (3.1%) | 33 (11.5%) | 34 (10.6%) |
 GOFL | 5 (15.6%) | 22 (7.6%) | 27 (8.4%) |
1L platinum-free | |||
 Gem + nab-paclitaxel | 7 (21.9%) | 47 (16.3%) | 54 (16.9%) |
 Gem + S1 | 7 (21.9%) | 45 (15.6%) | 52 (16.3%) |